SCYNEXIS, Inc. Increase (Decrease) in Inventories
SCYNEXIS, Inc. (SCYX) reported Increase (Decrease) in Inventories of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2025-03-12
- SCYNEXIS, Inc. increase (decrease) in inventories for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in inventories for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in inventories for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in inventories for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- SCYNEXIS, Inc. increase (decrease) in inventories for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SCYNEXIS, Inc. increase (decrease) in inventories for fiscal 2023 was $8.85M, a 1929.59% increase from fiscal 2022.
- SCYNEXIS, Inc. increase (decrease) in inventories for fiscal 2022 was $436.00K, a 91.76% decline from fiscal 2021.
- SCYNEXIS, Inc. increase (decrease) in inventories for fiscal 2021 was $5.29M.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $0.00 derived: sum of 2 quarters · filed 2025-03-12 | $0.00 derived: sum of 3 quarters · filed 2025-03-12 | $0.00 10-K · filed 2025-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | $1.46M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $1.46M derived: sum of 3 quarters · filed 2025-03-12 | $4.29M derived: sum of 4 quarters · filed 2025-03-12 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $1.46M derived: sum of 2 quarters · filed 2025-03-12 | $4.29M derived: sum of 3 quarters · filed 2025-03-12 | $6.14M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $4.29M derived: sum of 2 quarters · filed 2025-03-12 | $6.14M derived: sum of 3 quarters · filed 2025-03-12 | $8.85M 10-K · filed 2025-03-12 |
| 2023-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $4.68M derived: sum of 2 quarters · filed 2024-11-06 | $7.39M 10-Q · filed 2024-11-06 | $8.30M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.56M 10-Q · filed 2024-08-08 | $5.47M derived: sum of 3 quarters · filed 2024-08-08 | $4.68M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.71M 10-Q · filed 2024-05-08 | $3.62M derived: sum of 2 quarters · filed 2024-05-08 | $2.82M derived: sum of 3 quarters · filed 2024-05-08 | |
| 2022-12-31 | $910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $113.00K derived: sum of 2 quarters · filed 2024-03-28 | $436.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$797.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$474.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $323.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $5.29M 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |